Abbonarsi

Predictive factors for hepatocellular carcinoma in chronic hepatitis B using structural equation modeling: a prospective cohort study - 28/10/21

Doi : 10.1016/j.clinre.2021.101713 
Laurent Lam a, b, Hélène Fontaine c, Marc Bourliere d, Clovis Lusivika-Nzinga b, Céline Dorival b, Dominique Thabut e, Fabien Zoulim f, François Habersetzer g, Tarik Asselah h, Jean-Charles Duclos-Vallee i, Jean-Pierre Bronowicki j, Philippe Mathurin k, Thomas Decaens l, Nathalie Ganne m, Dominique Guyader n, Vincent Leroy o, Isabelle Rosa p, Victor De Ledinghen q, Paul Cales r, Xavier Causse s, Dominique Larrey t, Olivier Chazouilleres u, Moana Gelu-Simeon v, Véronique Loustaud-Ratti w, Sophie Metivier x, Laurent Alric y, Ghassan Riachi z, Jérôme Gournay A, Anne Minello B, Albert Tran C, Claire Geist D, Armand Abergel E, François Raffi F, Louis D'Alteroche G, Isabelle Portal H, Nathanaël Lapidus a, b, Stanislas Pol c, I, Fabrice Carrat a, b,

for the ANRS/AFEF Hepather study group

a Assistance Publique-Hôpitaux de Paris, Sorbonne Université, Department of Public Health, Hôpital Saint-Antoine, Paris, France 
b Sorbonne Université, INSERM, Institut Pierre Louis d’Épidémiologie et de Santé Publique, Paris, France 
c Department of Hepatology, Assistance Publique-Hôpitaux de Paris, Hôpital Cochin, Paris, France 
d Department of Hepatology and Gastroenterology, Hôpital Saint-Joseph, Marseille, France 
e Sorbonne Université, Department of Hepatology and Gastroenterology, Groupe Hospitalier Pitié-Salpétrière, AP-HP, INSERM UMR-S938, Paris, France 
f Department of Hepatology, Hospices Civils de Lyon, INSERM U1052, Université de Lyon, Lyon, France 
g CIC, Inserm 1110 et Pôle Hépato-digestif des Hôpitaux Universitaires de Strasbourg, Université de Strasbourg, Strasbourg, France 
h INSERM UMR 1149, Hepatology, Hospital Beaujon, Centre de Recherche sur l’Inflammation, (CRI), University Paris Diderot, Clichy, France 
i AP-HP Hôpital Paul-Brousse, Centre Hépato-Biliaire, Villejuif, UMR-S 1193, Université Paris-Saclay, DHU HEPATINOV, Villejuif, France 
j Inserm U1254 and Department of Hepato-Gastroenterology, University Hospital of Nancy Brabois, Université de Lorraine, Vandoeuvre-les-Nancy, France 
k Service des Maladies de l’Appareil Digestif, Université Lille 2 and Inserm U795, France 
l Department of Hepatology and Gastroenterology, Centre Hospitalo-Universitaire, INSERM U1209, Université Grenoble Alpes, Grenoble, France 
m Department of Hepatology, Hôpitaux Universitaires Paris Seine-Saint-Denis, Site Jean Verdier, AP-HP, Bondy, France; Université Paris 13, Sorbonne Paris Cité et INSERM UMR 1162, Paris, France 
n CHU de Rennes, Service d’Hépatologie, Univ Rennes 1, Inra, Inserm, Institut NUMECAN (Nutrition, Métabolismes et Cancer), UMR A 1341, UMR S 1241, F-35033 Rennes, France 
o Department of Hepatology and Gastroenterology, Hôpital Henri Mondor, AP-HP, Université Paris-Est, INSERM U955, Créteil, France 
p Department of Hepatology and Gastroenterology, Centre Hospitalier Intercommunal, Créteil, France 
q Hepatology Unit, University Hospital Bordeaux and INSERM U1053, Bordeaux University, Pessac, France 
r Hepatology Department, University Hospital, Angers, France; HIFIH Laboratory, Angers University, Angers, France 
s Department of Hepatology and Gastroenterology, CHR Orléans, France 
t Liver Unit-IRB-INSERM 1183, Hôpital Saint Eloi, Montpellier, France 
u Department of Hepatology, Hôpital Saint-Antoine, AP-HP, Sorbonne Université, Paris, France 
v Service d'Hépato-Gastroentérologie, CHU de la Guadeloupe - Faculté de Médecine, Université des Antilles, Pointe-à-Pitre Cedex, F-97110, France - INSERM, UMR-S1085/IRSET, F-35043 Rennes, France 
w Department of Hepatology and Gastroenterology, CHU Limoges, U1248 INSERM, Univ. Limoges, F-87000 Limoges, France 
x Hepatology Unit, CHU Rangueil, 31059 Toulouse, France 
y Department of Internal Medicine and Digestive Diseases, CHU Purpan, UMR 152 Pharma Dev, IRD Toulouse 3 University, France 
z Department of Hepatology and Gastroenterology, CHU Charles Nicolle, Rouen, France 
A Gastroenterology and Hepatology Department, Institut des Maladies de l'Appareil Digestif, University Hospital of Nantes, Nantes, France 
B Department of Hepatology and Gastroenterology, University Hospital Dijon, INSERM UMR 1231, France 
C Digestive Center, Centre Hospitalier Universitaire de Nice, INSERM U1065-8, Nice, France 
D Department of Hepatology and Gastroenterology, Centre Hospitalier Régional, Metz, France 
E Department of Digestive and Hepatobiliary Diseases, Estaing University Hospital, Clermont-Ferrand, France; UMR 6602 CNRS-Sigma-Université Clermont Auvergne, Clermont-Ferrand, France 
F Department of Infectious Diseases, Hotel-Dieu Hospital - INSERM CIC 1413, Nantes University Hospital, Nantes, France 
G Unit of Hepatology, Hépatogastroentérologie, CHU Trousseau, 37044 Tours, France 
H Service d'Hépato-Gastroentérologie, Hôpital de la Timone, Aix-Marseille Université, AP-HM, Marseille, France 
I Université de Paris; Inserm U-1223 and ICD, Institut Pasteur, Paris, France 

Corresponding author at: Institut Pierre Louis d'Épidémiologie et de Santé Publique, 27, rue Chaligny, 75571, Paris Cedex 12, France.Institut Pierre Louis d'Épidémiologie et de Santé Publique27, rue ChalignyParis Cedex 1275571France

Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.

pagine 14
Iconografia 3
Video 0
Altro 0

Highlights

We explored the pathways leading to hepatocellular carcinoma in hepatitis B disease.
The relationships between clinical characteristics and the cancer were analyzed.
Liver fibrosis has a key role in the occurrence of hepatocellular carcinoma.
The risk of occurrence is increased among elderly men with a metabolic syndrome.
Excessive alcohol consumption is also associated with a higher risk.

Il testo completo di questo articolo è disponibile in PDF.

Abstract

Background & Aims

The factors predicting hepatocellular carcinoma (HCC) occurrence in chronic hepatitis B need to be precisely known to improve its detection. We identified pathways and individual predictive factors associated with HCC in the ANRS CO22 HEPATHER cohort.

Methods

The study analyzed HBV-infected patients recruited at 32 French expert hepatology centers from August 6, 2012, to December 31, 2015. We excluded patients with chronic HCV, HDV and a history of HCC, decompensated cirrhosis or liver transplantation. Structural equation models were developed to characterize the causal pathways leading to HCC occurrence. The association between clinical characteristics (age, gender, body-mass index, liver fibrosis, alcohol consumption, smoking status, diabetes, hypertension, dyslipidemia, alpha-fetoprotein, HBV DNA levels, antiviral therapy) and incident HCC was quantified.

Results

Among the 4489 patients included, 33 patients reported incident HCC. The median follow-up was 45.5 months. Age (β = 0.18 by decade, 95% CI 0.14−0.23), male gender (β = 0.23, 95% CI 0.18−0.29), metabolic syndrome (β = 0.28, 95% CI 0.22−0.33), alcohol consumption (β = 0.09, 95% CI 0.05−0.14) and HBV DNA (β = 0.25, 95% CI 0.170.34) had a significant and direct effect on the occurrence of advanced liver fibrosis. Liver fibrosis (β = 0.71, 95% CI 0.55−0.87) predicted, in turn, the occurrence of HCC.

Conclusions

Liver fibrosis mediates the effects of age, gender, alcohol, metabolic syndrome and HBV DNA on the occurrence of HCC. Elderly men with chronic hepatitis B, risky alcohol use, advanced liver fibrosis, metabolic syndrome and high HBV DNA levels should be monitored closely to detect the development of HCC.

Il testo completo di questo articolo è disponibile in PDF.

Abbreviations : AFEF, AFP, ALP, ANR, ANRS, AST, BMI, CFI, CPP, DGS, DNA, EASL, ENT, FIB-4 index, GGT, HBeAg, HBV, HCC, HCV, HDL, HIV, HTN, INR, INSERM, MELD, NAFLD, NNFI, PAL, PNPLA3, RMSEA, SEM, SRMR, TDF, ULN

Keywords : Hepatocellular carcinoma, Hepatitis B virus, Hepatocarcinogenesis, Liver cancer, Epidemiology


Mappa


© 2021  Elsevier Masson SAS. Tutti i diritti riservati.
Aggiungere alla mia biblioteca Togliere dalla mia biblioteca Stampare
Esportazione

    Citazioni Export

  • File

  • Contenuto

Vol 45 - N° 5

Articolo 101713- Settembre 2021 Ritorno al numero
Articolo precedente Articolo precedente
  • Animal naming test for the assessment of minimal hepatic encephalopathy in Asian cirrhotic populations
  • Yundong Qu, Tao Li, Chunlei Lin, Feng Liu, Shuo Wu, Lei Wang, Qian Ye
| Articolo seguente Articolo seguente
  • Cellular communication network factor 1 (CCN1) knockdown exerts a protective effect for hepatic ischemia/reperfusion injury by deactivating the MEK/ERK pathway
  • Huanqiu Liu, Ji Li, Chengwei Jiang, Tong Yuan, Haichun Ma

Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.

Già abbonato a @@106933@@ rivista ?

Il mio account


Dichiarazione CNIL

EM-CONSULTE.COM è registrato presso la CNIL, dichiarazione n. 1286925.

Ai sensi della legge n. 78-17 del 6 gennaio 1978 sull'informatica, sui file e sulle libertà, Lei puo' esercitare i diritti di opposizione (art.26 della legge), di accesso (art.34 a 38 Legge), e di rettifica (art.36 della legge) per i dati che La riguardano. Lei puo' cosi chiedere che siano rettificati, compeltati, chiariti, aggiornati o cancellati i suoi dati personali inesati, incompleti, equivoci, obsoleti o la cui raccolta o di uso o di conservazione sono vietati.
Le informazioni relative ai visitatori del nostro sito, compresa la loro identità, sono confidenziali.
Il responsabile del sito si impegna sull'onore a rispettare le condizioni legali di confidenzialità applicabili in Francia e a non divulgare tali informazioni a terzi.


Tutto il contenuto di questo sito: Copyright © 2024 Elsevier, i suoi licenziatari e contributori. Tutti i diritti sono riservati. Inclusi diritti per estrazione di testo e di dati, addestramento dell’intelligenza artificiale, e tecnologie simili. Per tutto il contenuto ‘open access’ sono applicati i termini della licenza Creative Commons.